About
Betaliq is a collaboration between Novaliq, GMBH, and BLP Management Group, LLC. It was formed to develop ophthalmic beta-blockers using Novaliq’s patented EyeSol non-water formulation technology. The company is developing two beta-blockers, for the treatment of glaucoma. BTQ 1901 is an EyeSol based formulation of a potent selective beta-blocker that has not previously been used to treat glaucoma. BTQ 1902 is an EyeSol based formulation of timolol, the most commonly prescribed beta-blockers.
Region context
Betaliq is one of 6 Biotechnology companies we track in Tampa Bay, based in Tampa — about 5% of the region's 129 startups.
Tampa Bay — cybersecurity, fintech, and a growing health-tech cluster.
See the full Tampa Bay ecosystem →